<DOC>
	<DOCNO>NCT02930954</DOCNO>
	<brief_summary>This single arm phase II clinical trial , aim evaluate effectiveness combination gefitinib doublet chemotherapy antiangiogenesis advance non-small cell lung cancer patient EGFR activate mutation , accompany Bim deletion low activate EGFR mutation abundance .</brief_summary>
	<brief_title>Gefitinib Combined With Chemotherapy Antiangiogensis Patients With Bim Deletion Low EGFR Mutation Abundance</brief_title>
	<detailed_description>BIM deletion polymorphism low EGFR mutation abundance poor clinical response marker EGFR-TKIs NSCLC patient EGFR mutations.This phase II clinical trial investigate efficacy combination treatment patient harbor risk factor . Advanced EGFR mutate NSCLC Patients Bim deletion EGFR low mutation abundance randomizely divide three treatment group : A : Gefitinib 250mg Qd B : Gefitinib 250mg Qd combine doublet chemotherapy : Pemetrexed ( 500mg/m²day 1 intravenously ) plus carboplatin ( AUC=5 , day 1 , intravenously ) every 21 day , Gemcitabine ( 1000 mg/m² day 1 , day8 , intravenously ) plus carboplatin ( AUC=5 , day 1 , intravenously ) every 21 day C : Gefitinib 250mg Qd combine bevacizumab 7.5mg/kg intravenously per 21 day .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically document , locally advanced recurrent ( stage IIIb amenable combined modality treatment ) metastatic ( stage IV ) nonsmall cell lung cancer , anticancer treatment naiive EGFR exon 19 deletion exon 21 L858R . Bim deletion realtime PCR , low abundance EGFR mutation , 19Del less 4.9 % , L858R le 9.5 % . ECOG performance status ≤ 1 . Patients must measurable disease accord RECIST ( version 1.1 ) criterion . Life expectancy least 12 week Written ( sign ) inform Consent participate study . Adequate organ function define follow criterion : Liver function : SGOT ( AST ) SGPT ( ALT ) ≤ 2.5 X ULN absence liver metastases 5 X ULN case liver metastasis . Total bilirubin ≤ 1.5ULN . Bone marrow function : Granulocyte count ≥ 1,500/mm3 platelet count ≥100,000/mm3 hemoglobin ≥90g/dl . Renal function : serum creatinine ≤ 1.5 ULN creatinine clearance ≥ 60 ml/min . ( base modify CockcroftGault formula ) . For female childbearing potential negative serum/urine pregnancy test must obtain within 48 hour enrollment . Postmenopausal woman must amenorrhoeic least 12 month consider nonchildbearing potential . Patients prior chemotherapy systemic anticancer therapy include target therapy target HER family member ( erlotinib , gefitinib , cetuximab , trastuzumab , etc ) . Previous adjuvant neoadjuvant treatment nonmetastatic disease permit complete ≥ 6 month enrollment . Patients history malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer ) . Patients brain metastasis spinal cord compression . It permit patient treat surgery and/or radiation evidence stable disease least 4 week . Patients risk ( investigator 's opinion ) transmit human immunodeficiency virus ( HIV ) blood body fluid . lactate woman Sexually active male female ( childbearing potential ) unwilling practice contraception study . Unwilling write inform consent participate study unwilling receive followup Tumor invade big vessel close big vessel ( less 5mm ) Obvious cavity necrosis form tumor , Uncontrolled hypertension , Myocardial ischemia infarction stage II , cardiac insufficiency . Abnormal coagulation ( INR &gt; 1.5 PT &gt; ULN+4 , APTT &gt; 1.5 ULN ) , bleed tendency receive coagulation therapy Hemoptysis , 2.5ml daily Thrombosis 12 month , include pulmonary thrombosis , stoke , deep venous thrombosis . Unhealed bone fracture wound long time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NSCLC , EGFR , Bim , mutation abundance</keyword>
</DOC>